Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Evrysdi (risdiplam) for the treatment of patients with spinal muscular atrophy
- Imfinzi (durvalumab) for the treatment of patients with lung cancer and pleural mesothelioma
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
